Suchergebnisse - "Saif, Muhammad Wasif"

PubPharm (9)

1

The safety of lanreotide for neuroendocrine tumor

enthalten in: Expert opinion on drug safety | 2019

von Godara, A. | Siddiqui, N. | Byrne, M. | +1

2

The safety of lanreotide for neuroendocrine tumor

enthalten in: Expert opinion on drug safety | 2019

von Godara, A. | Siddiqui, N. | Byrne, M. | +1

3

Hypersensitivity reactions associated with oxaliplatin and their clinical management

enthalten in: Expert opinion on drug safety | 2014

von Toki, M. | Saif, M. | Syrigos, K.

4

Hypersensitivity reactions associated with oxaliplatin and their clinical management

enthalten in: Expert opinion on drug safety | 2014

von Toki, M. | Saif, M. | Syrigos, K.

5

Capecitabine and hand-foot syndrome

enthalten in: Expert opinion on drug safety | 2011

von Saif, M.

6

Capecitabine and hand-–foot syndrome

enthalten in: Expert opinion on drug safety | 2011

von Saif, M.

7

Chronic octreotide therapy can induce pancreatic insufficiency : a common but under-recognized adverse effect

enthalten in: Expert opinion on drug safety | 2010

von Saif, M. | Larson, H. | Kaley, K. | +1

8

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival

enthalten in: Expert opinion on drug safety | 2009

von Saif, M. | Hashmi, S. | Bell, D. | +1

9

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase-dihydropyrimidine dehydrogenase ratio and its correlation with survival

enthalten in: Expert opinion on drug safety | 2009

von Saif, M. | Hashmi, S. | Bell, D. | +1

1
[1]